Sign in
Taking people in SpainPhase 1/2

Tests the safety of CCS1477 in adults with advanced blood cancers

Tests the new drug CCS1477 alone and combined in adults with advanced blood cancers.

Key facts

Who runs it
Cellcentric Limited
Where
Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid, Pamplona, and Valencia, SpainSee the 11 sites
Registry title
A first time in man study to look at the safety of the experimental drug CCS1477 and what effects it has on cancers that affect the blood, bone marrow, lymph and lymphatic system.
Status
Recruiting
Phase
Phase 1/2
People taking part
16 people, planned
Started
13 May 2025
Expected to end
28 Feb 2027
Type of study
Interventional
Record updated
5 November 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose blood or bone marrow cancer (AML, higher-risk MDS, multiple myeloma or non-Hodgkin lymphoma) came back or did not respond to standard treatment.

Age
18 years or older
Sex
Men and women
Disease stage
Relapsed or refractory AML, higher-risk MDS, multiple myeloma or non-Hodgkin lymphoma (B-cell or T-cell). Acute promyelocytic leukemia (APL) is excluded. Multiple myeloma needs measurable disease. ECOG performance status of 1 or less for myeloma in Part D3, 2 or less for all other arms.
Earlier treatment
Must have had standard therapy and must not need urgent cytoreductive therapy. Higher-risk MDS: at least 4 cycles of a hypomethylating agent. Some myeloma parts need at least 2 prior therapies including lenalidomide and a proteasome inhibitor.

Main reasons for not taking part

  • Another cancer in the past, with a few exceptions
  • Spinal cord compression or cancer in the central nervous system
  • Severe or uncontrolled illness, such as heart disease or active infection (including hepatitis B, hepatitis C, HIV)
  • Pregnant or breast-feeding women
  • Certain medicines or recent treatment, surgery or radiotherapy before the first dose

The registry criteria, word for word

Show all 19 criteriaShow less

Who can take part

  • Written informed consent
  • Females must agree to use highly effective contraceptive measures (if sexually active), must not be breast feeding & must have a negative serum pregnancy test prior to start of dosing if of child-bearing potential, or must have evidence of non-child-bearing potential by fulfilling one of the following criteria at screening: • Post-menopausal defined as aged more than 50 years & amenorrhoeic for at least 12 months following cessation of all exogenous hormonal treatments. • Documentation of irreversible surgical sterilisation by hysterectomy, bilateral oophorectomy or bilateral salpingectomy but not tubal ligation. • Amenorrhoeic for 12 months & serum follicle-stimulating hormone, luteinizing hormone & plasma oestradiol levels in the postmenopausal range for the institution. Note: All patients receiving pomalidomide or lenalidomide must fulfil the conditions of the Pregnancy Prevention Programme. Refer to the protocol for additional inclusion criteria for combination arms
  • Willing&able to participate in all required evaluations and procedures
  • Men&women ≥18 years
  • ECOG performance status of ≤1 - for multiple myeloma patients in Part D3 and ECOG ≤ 2 for all other arms
  • Patients with confirmed relapsed or refractory haematological malignancies (NHL, MM, AML & higher risk MDS). Patients will include: • B-cell non-Hodgkin lymphoma - DLBCL, FL, MCL & Burkitt lymphoma • T-cell non-Hodgkin lymphoma • Multiple myeloma o Patients must have measurable disease by IMWG criteria defined as either serum M protein ≥0.5g/dL, or urine ≥200mg/24h, or involved SFLC ≥ 10mg/dL with abnormal FLC ratio • AML/secondary AML (patients with acute promyelocytic leukemia (APL) (FAB subtype M3) will be excluded) • Higher-risk MDS; according to revised IPSS-R
  • Must have received standard therapy. Must not require urgent cytoreductive therapy • NHL – patients must have exhausted or be ineligible for standard therapeutic options as available in the relevant geographical region; patient should not be eligible for hematopoietic stem cell transplantation; DLBCL patients should have received, or waiting for, CAR T cell treatment, if eligible and available; patients with indolent lymphomas must meet criteria for systemic therapy treatment. Patients should not be eligible for allogenic transplantation. • MM patients (except Parts D3), selected cohorts in D2; and D15-D18)) must have exhausted or be ineligible for standard therapeutic options as available in the relevant geographical region. For Parts D3 - (and selected small cohorts expansions in D2) MM patients must have received at least 2 prior therapies including lenalidomide and a proteasome inhibitor. • For Parts D15-D18 – patients must be triple class exposed (a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody), and where treatment with elranatamb or teclistamab is recommended per local standard practice. • AML–relapsed or refractory following standard therapeutic options, including non-intensive therapy and targeted agents, as applicable considering disease and patient characteristics as well as availability of therapy in the relevant geographical region • Higher-risk MDS patients must have previously failed treatment with at least 4 cycles of a hypomethylating agent (if applicable)
  • Adequate haematologic function • Absolute neutrophil count (ANC) ≥1000 cells/mm3 (1.0 x 109/L) or ≥750 cells/mm3 in patients with Duffy null phenotype if this is considered their normal baseline • Platelet count ≥75,000 cells/mm3 (75 x 109/L), screening result should be independent of platelet transfusion for at least 3 days. • Haemoglobin level ≥80 g/L. • For further details on supportive medications see restrictions (Section 4.3.3) This criterion does not apply to AML/MDS patients. Patients with other malignancies involving bone marrow with parameters below the threshold may be considered eligible following discussion with the medical monitor • For AML, WBC must be <10,000/μl
  • Adequate organ function at screening
  • Duration of the study & for 1 week after the last study medication administration (CCS1477 or combination agent), sexually active male patients must be willing to use barrier contraception i.e. condoms (with spermicide if locally approved for use) with all sexual partners. Where the sexual partner is a 'woman of child-bearing potential' who is not using effective contraception, men must use a condom (with spermicide if locally approved for use) & another form of contraception during the study & for 6 months after the last dose of study medication (CCS1477 or combination agent)

Who cannot take part

  • With the exception of alopecia, and CTCAE Grade 2 neuropathy, any unresolved toxicities from prior therapy > Grade 1 at the time of starting study treatment
  • History of prior malignancy except for the following: • Adequately treated carcinoma in situ or non-melanomatous skin cancer • Malignancy treated with curative intent or in remission for >6 months after the last therapy may be eligible. Maintenance treatment is allowed. Note: Patients with a history of any haematological malignancy (other than indications included in the protocol) may be included following discussion with the medical monitor
  • History of severe allergic or anaphylactic reactions or any known severe allergies to any active or inactive ingredients in the study medications (CCS1477 and/or pomalidomide, lenalidomide,dexamethasone, isatuximab, ixazomib, bortezomib, elranatamab, teclistamab, posaconazole, azacitidine or venetoclax as applicable)
  • Treatment with any of the following: • Any investigational agent, chemotherapy, immunotherapy or anticancer agents from a previous clinical study within 14 days or 5 half-lives of first dose of study treatment. • Strong inducers of CYP3A4 taken within 4 weeks of the first dose of study treatment or whilst on study treatment • Strong inhibitors of CYP3A4 and or P-gp taken within 2 weeks of the first dose of study treatment or while on study treatment. The potent CYP3A4 inihibitor posaconazole is allowed in patients participating in the posaconazole DDI part of the study. Following review of the posaconazole DDI data, and with the agreement of the Safety Review Committee, concomitant use of posaconazole may be permitted thereafter in the study. • CYP3A4 and/or CYP2B6 and/or P-gp and/or OATP1B1 sensitive substrates and substates with narrow therapeutic index taken within 2 weeks of the first dose of study treatment & during Cycle 1. Note - Patients may receive pravastatin or fluvastatin (with monitoring for potential toxicities), or atorvastatin or simvastatin at 10mg daily dose only. • CYP2C8 sensitive and moderate substrates taken within 2 weeks of the first dose of study treatment and duryng Cycle 1. • Herbal medications taken within 7 days of the first dose of study treatment (4 weeks for St John's wort) or while on study treatment. • Radiotherapy with a wide field of radiation or to more than 30% of the bone marrow within 4 weeks of the first dose of study treatment; palliative radiotherapy to ≤30% of the bone marrow within 2 weeks of the first dose of study treatment. • Steroids use >10mg daily (or 20mg daily for NHL) prednisolone or equivalent within 2 weeks of the first dose of study treatment. Replacement therapy steroids (even exceeding the above daily dose), given in the context of a transfusion, inhaled, nasal, topical and ophthalmic steroids are allowed. Note: For control of lymphoma related symptoms, patients may have received a brief (<7days) course of systemic steroids (≤ 100 mg prednisone equivalent per day) prior to initiation of study therapy. MM patients may receive >10mg daily if discussed and agreed with the medical monitor. • Medications with known risk of QT/QTc interval prolongation should be avoided concomitantly with CCS1477 unless essential in clinical management of the patient. If unavoidable, additional monitoring of potential QT/QTc interval prolongation is warranted • Major surgery within 4 weeks of the first dose of study treatment. • Shorter wash-out may be considered for some medications or palliative radiotherapy after discussion with medical monitor
  • Any evidence of severe or uncontrolled systemic disease (e.g. current unstable or uncompensated respiratory or cardiac conditions; recent history of significant cardiac incidents, eg. significant cardiac dysfunction (congestive heart failure [NY Heart Association Class III or IV]; myocardial infarction within 12 months of starting study; unstable or poorly controlled angina pectoris) history of risk factors for torsades de pointes (e.g. heart failure, hypokalemia, family history of long QT syndrome or clinically significant arrhythmia; uncontrolled diabetes; history of, or active, bleeding diatheses; uncontrolled active systemic infection, including hepatitis B&C and human immunodeficiency virus (HIV), or active HBV, HCV, SARS-CoV2 (for patients receiving elranatamab or teclistamab) which in the investigator’s opinion makes it undesirable for the patient to participate in the study or which would jeopardise compliance with the protocol
  • Active or unresolved spinal cord compression or CNS infiltration
  • Repeatable QTcF prolongation (>470 msec)
  • Female patients who are pregnant or breast-feeding at any time during the study
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements. Refer the protocol for additional exclusion criteria for combination arms

Where in Spain

  • Institut Catala d'OncologiaBadalona, SpainTaking people
  • Hospital Clinic de BarcelonaBarcelona, SpainTaking people
  • Institut Catala D'oncologiaL'Hospitalet de Llobregat, SpainTaking people
  • Clinica Universidad de NavarraMadrid, SpainTaking people
  • Hospital General Universitario Gregorio MarañónMadrid, SpainTaking people
  • Hospital Universitario 12 de OctubreMadrid, SpainTaking people
  • Hospital Universitario de la PrincesaMadrid, SpainTaking people
  • Hospital Universitario Infanta LeonorMadrid, SpainTaking people
  • Hospital Universitario Ramón y CajalMadrid, SpainTaking people
  • Clínica Universidad de navarraPamplona, SpainTaking people
  • Hospital Universitario Y Politecnico La FeValencia, SpainTaking people

About the trial

What the trial wants to find out

To investigate the safety and tolerability of CCS1477 when given as monotherapy and in combination in patients with blood/bone marrow cancers.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
An open-label Phase I/IIa study to evaluate the safety and efficacy of CCS1477 as monotherapy and in combination in patients with advanced haematological malignancies
Plain-language title
Tests the safety of CCS1477 in adults with advanced blood cancersGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
5 November 2026